Neurology Updates

Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) show similarities in pathology and genetics, hinting at shared…

This article provides a comprehensive review of the studies using non-invasive brain and spinal stimulation in motor neuron disease, with a focus on…

This study provides further insights in the consequences of mislocalization of the protein TDP-43 from the nucleus to the cytoplasm which is a…

Virtual palliative care consultation for people with ALS, and their caregivers, was found to be helpful and did not take too much energy or cause…

A modified RT-QuIC assay combined with immunoprecipitation for the detection of α-synuclein fibrils appears to be a good blood biomarker for…

The FDA has approved Omaveloxolone for the treatment of Friedrich ataxia (FA). Omaveloxone improved neurological function assessed with the modified…

Mader et al. dissect the MOG IgG effector mechanisms that characterize MOG-antibody-associated disease. FcR pathway mediates the MOG-Abs enhanced…

The study validated a screening questionnaire for pediatric narcolepsy, which showed high sensitivity and specificity in identifying affected…

A “Mini Linguistic State Examination”, was developed to assess and classify language disorders in patients with primary progressive aphasia (PPA).…

Rozanolixizumab is subcutaneous infused monoclonal antibody targeting the neonatal Fc receptor (FcRn) in adult with MG.

As already presented…

An interim analysis of the phase 3 open-label extension study (RAISE-XT) testing zilucoplan (a self-administered subcutaneous complement C5 inhibitor)…

Eculizumab (Soliris; Alexion) is an intravenous complement C5 inhibitor originally approved by FDA and EMA in adult’s patient with anti-acetylcholine…